High-yield points
- AADC deficiency: bilateral intraputaminal AAV2 gene therapy gave durable motor gains (more than 5 years), better in younger children, with transient dyskinesia . MR-guided cannula delivery confirms coverage, with no adverse events attributed to the cannula .
- CLN2 (Batten): intraventricular cerliponase alfa every 2 weeks slows decline (0.27 vs 2.12 points per 48 weeks) . Devices fail and get infected: complications in 12 of 26 operations, and revised reservoirs last much shorter (301 vs 2,317 days) .
- SMA with fusion: laminectomy window (9 of 11 successful) or intrathecal port (2 of 8 leaks, no infections) .
- Pipeline: intrathecal ASOs (zorevunersen for Dravet ); ICV and intrathecal gene therapy for Rett . Expect more access-device work.
Landmark papers
- Schulz et al., N Engl J Med 2018: intraventricular cerliponase alfa for CLN2. Decline was 0.27 vs 2.12 points per 48 weeks, at the cost of device failures and infections .
- Tai et al., Mol Ther 2022: intraputaminal eladocagene exuparvovec in 26 children with AADC deficiency, with motor and cognitive gains sustained beyond 5 years .
- Laux et al., N Engl J Med 2026: zorevunersen for Dravet syndrome, an investigational, potentially disease-modifying ASO for a developmental and epileptic encephalopathy, given intrathecally .
A new role for pediatric neurosurgeons is getting a drug or vector past the blood–brain barrier. Enzyme replacement, gene therapy and antisense oligonucleotides (ASOs) for rare inherited disorders increasingly need:
- stereotactic infusion into a deep brain target (AADC deficiency);
- intraventricular access devices for repeated dosing (CLN2 disease);
- intrathecal access when the spine is fused or deformed (spinal muscular atrophy);
- intracerebroventricular or intrathecal delivery of agents now in trials (Dravet syndrome, Rett syndrome and others).
The neurosurgeon owns the targeting, the device and its complications, and should be part of the treating team from the start (see caveats).
AADC deficiency: intraputaminal gene therapy
- The disease: a defect in aromatic L-amino acid decarboxylase (DDC gene) blocks dopamine and serotonin synthesis. It presents in infancy with severe motor disability, hypotonia, oculogyric crises, and autonomic and sleep problems .
- The therapy: eladocagene exuparvovec, an AAV2 vector carrying the human DDC gene, infused bilaterally into the putamen in one operation.
- Long-term open-label data (26 children without head control) :
- rapid motor and cognitive gains within 12 months, sustained beyond 5 years;
- increased dopamine production on PET and neurotransmitter testing;
- improved mood, sweating, temperature control and oculogyric crises;
- younger age predicted greater improvement;
- no treatment-related brain injury; CSF leaks were managed routinely;
- most children had mild to moderate dyskinesia that resolved within months.
- MR-guided delivery with an MR-compatible cannula (phase 2, 13 children) :
- CSF homovanillic acid (a dopamine metabolite) rose significantly by 48 weeks;
- by 48 weeks, 9 of 12 had full head control, 4 sat unassisted, and 2 walked to a toy;
- of 260 adverse events, 259 were judged unrelated and 1 likely unrelated to the cannula, and no deaths;
- real-time MRI confirmed cannula placement and infusate coverage of the putamen.
- An alternative midbrain target (7 children) :
- convection-enhanced delivery to the substantia nigra and ventral tegmental area, covering 98% and 70% of the targets;
- oculogyric crises resolved in 6 of 7 by 3 months;
- at 12 months, 6 of 7 had normal head control.
- Neurosurgical points (see caveats):
- anesthesia is high risk, because of autonomic instability and oculogyric crises; plan with an experienced team;
- plan trajectories to cover the putamen with multiple deposits per side, avoiding the ventricles and sulci (reflux and leak);
- watch for dyskinesia in the first months after surgery as dopamine production starts.
CLN2 disease: intraventricular enzyme replacement
- The disease: CLN2 (late-infantile neuronal ceroid lipofuscinosis) is a lysosomal disorder from tripeptidyl peptidase 1 deficiency. It causes progressive dementia in children , typically with seizures and then rapid loss of motor and language function (see caveats).
- The therapy: cerliponase alfa, recombinant TPP1, infused into the lateral ventricle every 2 weeks.
- Pivotal study (23 children aged 3–16, compared with 42 historical controls) :
- motor–language decline of 0.27 vs 2.12 points per 48 weeks;
- the median time to a 2-point decline was not reached with treatment vs 345 days in controls;
- device problems were among the serious adverse events: device failure and device infections in 2 patients, which needed antibiotics and device replacement.
- Ventricular access device survival (17 children) :
- 26 operations (17 insertions, 9 revisions);
- 12 operations were associated with a complication:
- CSF infection in 6 (Propionibacterium/Cutibacterium and staphylococci most often);
- swelling at the site preventing infusion in 3;
- leak or wound breakdown in 2;
- obstruction in 1.
- median device survival 2,317 days for primary reservoirs vs 301 days after revision.
- Neurosurgical points (see caveats):
- use strict asepsis for every puncture: hundreds of punctures over a lifetime;
- rotate puncture sites on the dome;
- thin scalp in small children erodes; consider a chest-sited port connected to the ventricular catheter;
- treat a device infection by removal, antibiotics and delayed replacement (see shunt infections).
Spinal muscular atrophy: intrathecal access after spinal fusion
- The problem: nusinersen (an ASO) is given by repeated lumbar puncture. Many children with SMA have scoliosis and posterior spinal fusion, which blocks the usual route.
- Lumbar laminectomy window (11 patients with solid fusion) :
- 9 of 11 started intrathecal therapy through the window, with a mean of 11.7 injections each;
- incidental dural tears in 3, managed without complications;
- no hardware revisions or major adverse events over a mean of 48.8 months.
- Subcutaneous port with an intrathecal catheter (8 patients) :
- catheter leak in 2, fixed by resuturing;
- no infection, dislocation, kinking or obstruction at a median of 19 months.
- Other options (see caveats):
- plan with the spine surgeon before fusion, leaving a window in the fusion;
- image-guided transforaminal or cervical (C1–C2) punctures.
In the pipeline
- Dravet syndrome: zorevunersen, an ASO that up-regulates Nav1.1 (SCN1A), given intrathecally (phase 1–2a and extension studies, 81 children) :
- in the 70 mg group, the median change in convulsive seizure frequency ranged from −59% to −91% across months of the extension studies;
- post-lumbar-puncture syndrome in 25%; raised CSF protein in 45% in the extension studies;
- 2 deaths from SUDEP and 1 from malnutrition.
- Repeated intrathecal dosing for years may create demand for intrathecal ports (see caveats).
- Rett syndrome (MECP2) :
- trofinetide is the first approved drug (oral);
- two gene-replacement therapies are in trials:
- TSHA-102, delivered intrathecally;
- NGN-401, delivered intracerebroventricularly;
- the challenge is a narrow window between too little MeCP2 and overexpression toxicity. A fatal hyperinflammatory adverse event has occurred.
- Other targets (see caveats):
- ASOs for Angelman syndrome (intrathecal);
- AAV gene therapies for Canavan disease, GM1 gangliosidosis and other leukodystrophies (intraparenchymal or intraventricular);
- intracerebroventricular enzyme replacement for some mucopolysaccharidoses.
- Common neurosurgical themes:
- access devices that last a childhood;
- infection control;
- image-guided targeting, increasingly with real-time MRI and convection-enhanced delivery ;
- anesthetic risk in fragile children.
Related topics
- Deep Brain Stimulation for Dystonia in Children: stereotactic targeting in movement disorders.
- Shunt Infections: managing infected ventricular devices.
- Surgical Management of Spasticity in Children (Botulinum Toxin, Phenol, Intrathecal Baclofen, Selective Dorsal Rhizotomy): intrathecal pumps and catheters.
- Epilepsy Surgery in Children: Overview: surgical options in genetic epilepsies.
- Diffuse Intrinsic Pontine Glioma (DIPG): ventricular access and convection-enhanced delivery in trials.
- Lumbar Puncture in Children: intrathecal access.
References
- Pearson TS, Gupta N, San Sebastian W, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat Commun 2021;12(1):4251. doi:10.1038/s41467-021-24524-8. PMID 34253733. verified
- Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther 2022;30(2):509–518. doi:10.1016/j.ymthe.2021.11.005. PMID 34763085. verified
- Curry DJ, Pearl PL, Stone SSD, et al. Pharmacodynamics, efficacy, and safety of intraputaminal eladocagene exuparvovec administered to pediatric patients with aromatic L-amino acid decarboxylase deficiency using an MR-compatible cannula: 48 weeks of follow-up. J Inherit Metab Dis 2026;49(2):e70151. doi:10.1002/jimd.70151. PMID 41724580. verified
- Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018;378(20):1898–1907. doi:10.1056/NEJMoa1712649. PMID 29688815. verified
- Craven CL, Gissen P, Bower R, et al. A survival analysis of ventricular access devices for delivery of cerliponase alfa. J Neurosurg Pediatr 2022;29(1):115–121. doi:10.3171/2021.7.PEDS21129. PMID 34624852. verified
- Potaczek T, Duda S, Adamczyk J. Surgical access for intrathecal therapy in spinal muscular atrophy with spinal fusion: long-term outcomes of lumbar laminectomy. J Clin Med 2025;14(12):4280. doi:10.3390/jcm14124280. PMID 40566025. verified
- Flotats-Bastardas M, Hahn A, Schwartz O, et al. Multicenter experience with nusinersen application via an intrathecal port and catheter system in spinal muscular atrophy. Neuropediatrics 2020;51(6):401–406. doi:10.1055/s-0040-1715481. PMID 33091940. verified
- Laux L, Sullivan J, Perry MS, et al. Zorevunersen in children and adolescents with Dravet syndrome. N Engl J Med 2026;394(10):969–982. doi:10.1056/NEJMoa2506295. PMID 41780062. verified
- Samanta D. Disease-modifying therapies for Rett syndrome: a review for neurologists. Front Neurol 2026;17:1766679. doi:10.3389/fneur.2026.1766679. PMID 41641323. verified
Verification (2026-11-18):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed.
- Numbers were checked against the PubMed abstracts. The −59% figure rounds the abstract's −58.82%.
Caveats:
- The following are standard teaching or common practice, not drawn from the cited abstracts:
- the neurosurgeon's role on the treating team;
- the clinical course of CLN2 beyond progressive dementia;
- AADC anesthetic risk, trajectory planning and the timing of dyskinesia;
- puncture asepsis and rotation, scalp erosion, chest-sited ports and infected-device management for CLN2;
- planning a fusion window before spinal fusion, and transforaminal or cervical punctures for SMA;
- the route of zorevunersen dosing (the abstract describes post-lumbar-puncture syndrome, implying lumbar intrathecal delivery) and future demand for intrathecal ports;
- the other pipeline targets (Angelman, Canavan, GM1, mucopolysaccharidoses).
- Regulatory approval status varies by country and changes quickly; check current labeling.
- Reference 6 includes young adults, and reference 7's patients were mostly adults (median age 21).
- The figure is an original schematic.